Scarica l'app Stockscreener
3.64
2.82%
0.10
Pre-mercato:
3.59
-0.05
-1.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$3.54
Aprire:
$3.6
Volume 24 ore:
16.11M
Relative Volume:
0.76
Capitalizzazione di mercato:
$1.89B
Reddito:
$43.69M
Utile/perdita netta:
$-715.54M
Rapporto P/E:
-2.011
EPS:
-1.81
Flusso di cassa netto:
$-450.20M
1 W Prestazione:
-3.45%
1M Prestazione:
-6.67%
6M Prestazione:
-19.47%
1 anno Prestazione:
-43.74%
Intervallo 1D:
$3.53
$3.76
Intervallo di 1 settimana:
$3.44
$3.79
Portata 52W:
$2.98
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.64 | 1.84B | 43.69M | -715.54M | -450.20M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
ARK Investment Management LLC Purchases 556,868 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. $RXRX Stake Cut by Amova Asset Management Americas Inc. - MarketBeat
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Earnings Jump And New Equity Offering Plans - simplywall.st
RECURSION PHARMACEUTICALS Director Sells 170,000 Shares - TradingView
Rafferty Asset Management LLC Purchases 394,022 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Uncovering a Potential 84.97% Upside in Biotech - DirectorsTalk Interviews
Recursion: Nvidia Sells Out, Collaboration Still Alive, Data Ahead (NASDAQ:RXRX) - Seeking Alpha
RXRX: Integrated platform, strong partnerships, and disciplined pipeline drive innovation and growth - TradingView
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Vanguard Group Inc. Purchases 3,708,975 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals Stock Hits Day Low of $3.33 Amid Price Pressure - Markets Mojo
Assessing Recursion Pharmaceuticals (RXRX) After A 51% One Year Share Price Decline - Sahm
Recursion’s REC-4881 Milestone And Cash Runway Shift Risk Reward Profile - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Recursion Pharmaceuticals : 2025 Shareholder Letter and Business Overview - marketscreener.com
Recursion’s First Clinical Signal And Sanofi Milestone Test AI Drug Thesis - Sahm
Recursion Pharmaceuticals Opens with 11.05% Gain Despite Recent Declines - Markets Mojo
Recursion Pharmaceuticals (RXRX) hits clinical milestones as 2025 revenue grows to $74.7M - MSN
Recursion Pharmaceuticals (RXRX) Hits Clinical Milestones as 2025 Revenue Grows to $74.7M - Yahoo Finance
Recursion Pharmaceuticals' (RXRX) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 Earnings Call Transcript - Insider Monkey
BofA Maintains Neutral on Recursion Pharmaceuticals (RXRX) Feb 25, 2026 - Meyka
Recursion Pharmaceuticals Q3 Loss Deepens Narrative Of Heavy Spending Over Limited US$5.2m Revenue - simplywall.st
Recursion Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-02-25 - Seeking Alpha
Recursion Pharmaceuticals: Q4 Earnings Snapshot - theheraldreview.com
Recursion Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
RXRX Showcased at NVIDIA’s GTC Conference as AI Labs Collaborate - timothysykes.com
Recursion Pharmaceuticals (RXRX) Stock Surges After Beating Q4 EPS and Revenue Estimates - MEXC
Recursion Pharmaceuticals Q4: Why My December Buy Call Was Too Optimistic (NASDAQ:RXRX) - Seeking Alpha
BofA cuts Recursion Pharmaceuticals stock price target on launch timing - Investing.com
Recursion (RXRX) Q4 2025 Earnings Call Transcript - AOL.com
Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Recursion stock jumps after solid Q4 beat (RXRX:NASDAQ) - Seeking Alpha
Recursion’s AI-Enabled Drug Discovery Wins Spotlight at NVIDIA’s Conference - timothysykes.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Earnings Results - MarketBeat
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - The Globe and Mail
What's Behind The Jump In Recursion Pharmaceuticals Stock? - Benzinga
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up Following Better-Than-Expected Earnings - MarketBeat
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Recursion Pharmaceuticals Receives Spotlight with AI-driven Innovations at NVIDIA’s GTC - StocksToTrade
Recursion Q4 2025 slides: AI platform delivers first clinical proof-of-concept - Investing.com UK
Earnings call transcript: Recursion Pharmaceuticals beats Q4 2025 forecasts - Investing.com
This $4 Stock Could Be Your Ticket to Millionaire Status - AOL.com
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion Pharmaceuticals reports Q4 EPS (21c), consensus (32c) - TipRanks
Recursion Pharmaceuticals earnings beat by $0.09, revenue topped estimates - Investing.com UK
RXRX stock soars pre-market on Q4 beat, Recursion CEO says company has ‘reached an inflection point’ - MSN
Recursion Highlights AI Validation, Extends Cash Runway to 2028 - TipRanks
Recursion Pharmaceuticals Q4 Loss Narrows, Revenue Rises - marketscreener.com
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - markets.businessinsider.com
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):